<DOC>
	<DOC>NCT02166827</DOC>
	<brief_summary>To evaluate the long-term efficacy of the NeuroAD system</brief_summary>
	<brief_title>Effects of a NeuroAD System, for the Treatment of Alzheimer Disease</brief_title>
	<detailed_description>To evaluate the long-term efficacy of the NeuroAD system in improvement of mild- to moderate Alzheimer patients' cognitive function</detailed_description>
	<mesh_term>Alzheimer Disease</mesh_term>
	<criteria>Main 1. Male or female age 6090 years 2. Patients diagnosed with mild or moderate stage of Alzheimer's Disease, according to the DSMIV criteria 3. MMSE score 18 to 26 4. Physical clearance for study participation as evaluated by the clinician 5. Spouse, family member or professional caregiver agree and capable of taking care for the participation of the patient in the study (answering questions regarding the patient's condition and assuming responsibility for medication) 6. Informed consent by the patient or by legally authorized person if appointed Main 1. CDR 0, 0.5 or 3 2. Severe agitation 3. Mental retardation 4. History of Epileptic Seizures or Epilepsy 5. Contraindication for performing MRI scanning 6. Contraindication for receiving TMS treatment according to a TMS questionnaire 7. Patients with metal implants in the head, (i.e. cochlear implants, implanted brain stimulators and neurostimulators, aneurysm clips) with the exception of metal implants in mouth 8. Cardiac pacemakers 9. Implanted medication pumps 10. Intracardiac lines 11. Significant heart disease 12. Currently taking medication that lower the seizure threshold</criteria>
	<gender>All</gender>
	<minimum_age>60 Years</minimum_age>
	<maximum_age>90 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>TMS</keyword>
	<keyword>Cognitive Stimulation</keyword>
	<keyword>NeuroAD</keyword>
</DOC>